Portola Pharmaceuticals Inc  

(Public, NASDAQ:PTLA)   Watch this stock  
Find more results for PTLA
+0.17 (0.87%)
Real-time:   9:51am GMT-4
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.54 - 20.23
52 week 18.20 - 52.89
Open 20.01
Vol / Avg. 30,102.00/748,218.00
Mkt cap 1,126.98M
P/E     -
Div/yield     -
EPS -4.45
Shares 56.50M
Beta 1.05
Inst. own 96%
Nov 1, 2016
Q3 2016 Portola Pharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Aug 30, 2016
Portola Pharmaceuticals Inc Conference Call regarding ANNEXA-4 Interim Results - Webcast
Aug 18, 2016
Portola Pharmaceuticals Inc Conference Call To Provide an Update on AndexXa
Aug 9, 2016
Q2 2016 Portola Pharmaceuticals Inc Earnings Call - Webcast
Aug 9, 2016
Q2 2016 Portola Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -1355.21% -1876.60%
Operating margin -1362.23% -1882.15%
EBITD margin - -1871.28%
Return on average assets -52.78% -49.27%
Return on average equity -66.51% -58.44%
Employees 137 -
CDP Score - -


270 East Grand Avenue, Suite 22
United States - Map
+1-650-2446864 (Phone)
+1-650-2467376 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Officers and directors

Charles J. Homcy M.D. Co-Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Hollings C. Renton III Independent Co-Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
William Lis Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Mardi C. Dier Chief Financial Officer, Executive Vice President
Age: 51
Bio & Compensation  - Reuters
John T. Curnutte M.D. Ph.D. Executive Vice President - Research & Development
Age: 63
Bio & Compensation  - Reuters
Tao Fu Executive Vice President, Chief Commercial and Business officer
Bio & Compensation  - Reuters
Laura A. Brege Director
Age: 58
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Director
Age: 64
Bio & Compensation  - Reuters
John H. Johnson Director
Age: 57
Bio & Compensation  - Reuters
David Carter Stump M.D. Director
Age: 66
Bio & Compensation  - Reuters